Ribociclib + Fulvestrant + Anastrozole + Letrozole + Exemestane

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Locoregional Recurrence

Conditions

Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer

Trial Timeline

Sep 13, 2022 → Aug 1, 2029

NCT ID

NCT05467891

About Ribociclib + Fulvestrant + Anastrozole + Letrozole + Exemestane

Ribociclib + Fulvestrant + Anastrozole + Letrozole + Exemestane is a phase 2 stage product being developed by Novartis for Locoregional Recurrence. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05467891. Target conditions include Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05467891	Phase 2	Recruiting	Sep 13, 2022	Aug 1, 2029	Locoregional Recurrence

Competing Products

1 competing product in Locoregional Recurrence

See all competitors

Product	Company	Stage	Hype Score
AZD2936	AstraZeneca	Phase 2	42